ABSTRACT
BACKGROUND: Appropriate use criteria have been developed for many tests using expert judgment, evidence-based practice and clinical experience. In this context, we report the opinions of practitioners about clonality assays in various clinical scenarios where cutaneous lymphoma is suspected. METHODS: An Appropriate Use Criteria Task Force sponsored by the American Society of Dermatopathology (ASDP) synthesized clinical scenarios for cutaneous lymphoproliferative disorders (LPDs). We conducted, summarized and presented a relevant literature search to an audience of 144 dermatopathologists with a variety of practice experiences at the 53rd Annual Meeting of the ASDP in Chicago, IL. RESULTS: Twenty-seven clinical scenarios for LPDs (13 T-cell and 14 B-cell) were defined. Forty relevant studies for T-cell receptor gene clonality assays and 20 relevant studies for IgH/IgK clonality assays were identified. Audience response data from participating dermatopathologists reflected a wide variety of approaches to the application of clonality assays in the evaluation of LPDs, based on practice setting, personal experience and test availability. CONCLUSIONS: Our clinical scenario analysis and literature review revealed well-supported clinical scenarios and identified opportunities for additional research to further define the utility of clonality assays in some clinical scenarios.
Subject(s)
Dermatology , Lymphoma, B-Cell/diagnosis , Lymphoma, T-Cell/diagnosis , Pathology , Skin Neoplasms/diagnosis , Clone Cells , Humans , Practice Patterns, Physicians'ABSTRACT
BACKGROUND: Dermatofibrosarcoma protuberans (DFSP) is a tumor of intermediate malignancy, which in selected circumstances can pose difficulty in diagnosis. Clear cell sarcoma (CCS) is a very rare aggressive soft tissue sarcoma that can be difficult to distinguish histologically from melanoma. METHODS: The current literature on t(17;22) COL1A1-PDGFB fluorescence in situ hybridization (FISH) assay in DFSP was reviewed. Also reviewed was the current literature on dual color break-apart EWSR1 FISH assay in CCS. Finally, the current utilization patterns of these tests was assessed in attendees of the American Society of Dermatopathology annual meeting (Chicago, 2016). RESULTS: The literature indicates that (17;22) COL1A1-PDGFB FISH assay has limited value for classic DFSP, where the diagnosis can be established by routine morphology and immunohistochemistry. Given the high specificity of the EWSR1 FISH assay and significant complexity in the diagnosis of CCS, this ancillary study is helpful in distinguishing CCS from melanoma. CONCLUSIONS: In attendees, t(17;22) COL1A1-PDGFB FISH testing for classic cases of DFSP is appropriately not being used by respondents. However, the literature sustains that it is useful in selected circumstances in which a definitive diagnosis is challenging. The majority of respondents are utilizing the EWSR1 FISH assay to distinguish CSS from melanoma as is supported by the literature.
Subject(s)
Chromosomes, Human, Pair 17/genetics , Chromosomes, Human, Pair 22/genetics , Dermatofibrosarcoma , In Situ Hybridization, Fluorescence/methods , Sarcoma, Clear Cell , Skin Neoplasms , Translocation, Genetic , Dermatofibrosarcoma/diagnosis , Dermatofibrosarcoma/genetics , Dermatofibrosarcoma/pathology , Humans , Sarcoma, Clear Cell/diagnosis , Sarcoma, Clear Cell/genetics , Sarcoma, Clear Cell/pathology , Skin Neoplasms/diagnosis , Skin Neoplasms/genetics , Skin Neoplasms/pathologyABSTRACT
BACKGROUND: Appropriate use criteria (AUC) provide physicians guidance in test selection, and can affect health care delivery, reimbursement policy and physician decision-making. OBJECTIVES: The American Society of Dermatopathology, with input from the American Academy of Dermatology and the College of American Pathologists, sought to develop AUC in dermatopathology. METHODS: The RAND/UCLA appropriateness methodology, which combines evidence-based medicine, clinical experience and expert judgment, was used to develop AUC in dermatopathology. RESULTS: With the number of ratings predetermined at 3, AUC were developed for 211 clinical scenarios involving 12 ancillary studies. Consensus was reached for 188 (89%) clinical scenarios, with 93 (44%) considered "usually appropriate," 52 (25%) "rarely appropriate" and 43 (20%) "uncertain appropriateness." LIMITATIONS: The methodology requires a focus on appropriateness without comparison between tests and irrespective of cost. CONCLUSIONS: The ultimate decision of when to order specific test rests with the physician and is one where the expected benefit exceeds the negative consequences. This publication outlines the recommendations of appropriateness-AUC for 12 tests used in dermatopathology. Importantly, these recommendations may change considering new evidence. Results deemed "uncertain appropriateness" and where consensus was not reached may benefit from further research.
Subject(s)
Dermatology , Evidence-Based Medicine , Pathology , Diagnostic Tests, Routine , Humans , United StatesABSTRACT
Bullous diseases are a group of dermatoses primarily characterized by the presence of vesicles (0.1-0.9 cm) or bullae (>1 cm). There are various categories of bullous disease: allergic, autoimmune, infectious, mechanical, and metabolic. These diseases affect individuals in all decades of life, but older adults, age 65 and older, are particularly susceptible to bullous diseases of all etiologies. The incidence of these disorders is expected to increase given the advancing age of the general population. In this comprehensive review, we will outline the common bullous diseases affecting older individuals and provide an approach to evaluation and management.
Subject(s)
Skin Diseases, Vesiculobullous , Humans , Aged , Skin Diseases, Vesiculobullous/diagnosis , Skin Diseases, Vesiculobullous/etiology , Skin Diseases, Vesiculobullous/therapySubject(s)
Alemtuzumab/therapeutic use , CD52 Antigen/genetics , Gene Expression Regulation , Lymphoma, T-Cell, Peripheral/drug therapy , Lymphoma, T-Cell, Peripheral/pathology , Skin Neoplasms/genetics , Antibodies, Monoclonal/therapeutic use , Biopsy, Needle , CD52 Antigen/metabolism , Female , Follow-Up Studies , Humans , Immunohistochemistry , Immunophenotyping/methods , Lymphoma, T-Cell, Peripheral/genetics , Male , Molecular Targeted Therapy/methods , Risk Assessment , Skin Neoplasms/drug therapy , Skin Neoplasms/pathology , Treatment OutcomeABSTRACT
A 35-year-old African American man presented with complaints of malodorous drainage from hypertrophic lesions on his occipital scalp (Figure 1, inset). The patient had no family history of keloid formation and no other keloids on his body. The hypertrophic mass on his scalp had been present for 10 years and had not been a result of any type of mechanical, surgical, or laser treatment. It corresponded to the distribution of a large vascular malformation over the occiput (Figure 1). The vascular malformation extended from the occipital scalp to the right parietal scalp, the right side of the face, neck, upper chest, and right arm, with varicosities and hypertrophy of the right upper extremity (Figure 2). The vascular malformation over the right parietal scalp and ear was characterized by bleb formation and hypertrophy of the right ear. The patient reported that no manipulation, including laser treatment, of the vascular malformation had been previously performed. He did state that a previous dermatologist had attempted serial surgical excision of the cerebriform nodules but retired during the course of treatment. He stated that the appearance of his keloid formation and port-wine stain had not changed during the past 10 years. A previous biopsy of a hypertrophic lesion showed histologic findings consistent with folliculitis keloidalis nuchae. Cephalexin 500 mg 4 times daily for 14 days was prescribed for the purulent drainage. A Doppler ultrasound was ordered of the right upper extremity to evaluate for an arteriovenous malformation and showed no evidence of venous thrombosis or arteriovenous malformation. On a second visit 2 weeks later, the hypertrophic lesions continued to show drainage. Clindamycin gel to be applied twice daily to the scalp was added. The patient also had magnetic resonance imaging with and without gadolinium contrast (Figure 3) ordered, which showed a large hypertrophic giant scalp keloid overlying the occipital and suboccipital region measuring 12x 19 cm. There was soft tissue thickening involving the right external ear, extending inferior to the right ear, overlying an intact parotid gland. There was no evidence of muscular or skull invasion.
Subject(s)
Acne Keloid/pathology , Klippel-Trenaunay-Weber Syndrome/complications , Scalp/pathology , Acne Keloid/etiology , Adult , Anti-Bacterial Agents/therapeutic use , Cephalexin/therapeutic use , Ear, External/blood supply , Ear, External/pathology , Folliculitis/etiology , Folliculitis/pathology , Humans , Klippel-Trenaunay-Weber Syndrome/pathology , Magnetic Resonance Imaging , Male , Scalp/blood supply , Ultrasonography, DopplerABSTRACT
BACKGROUND: The histogenesis and differentiation of eccrine tumors, including cylindroma, poroma, spiradenoma and syringoma, remains controversial. This controversy may be because of sporadic and incomplete studies of these neoplasms. METHODS: Ten examples each of normal eccrine structures and of four benign eccrine tumors are analyzed with antibodies to cytokeratin (CK) 7, CD34, CK6, CK10, smooth muscle actin (SMA) and CD10. These markers represent two different immunohistochemical stains for each part of the eccrine structure; CK7 and CD34 stain the secretory coil, CK6 and CK10 stain the straight duct and SMA and CD10 stain the myoepithelial cells. This redundancy in staining is performed on four benign eccrine tumors to better interpret the existing literature. RESULTS: We find that CK7 is a sensitive marker for the secretory coil; both cylindromas and spiradenomas express CK7. We also find that CK6 is a marker for the inner ductal cells, while CK10 is a marker for the middle ductal cells; syringomas express both these markers. SMA appears to be a more specific marker for myoepithelial cells surrounding normal eccrine coils, and none of the studied tumors express SMA or CD10. CONCLUSIONS: Our studies suggest that syringomas are tumors of the eccrine duct, while cylindromas and spiradenomas are tumors of the secretory coil.
Subject(s)
Adenoma, Sweat Gland , Antigens, CD34/biosynthesis , Biomarkers, Tumor/biosynthesis , Keratins/biosynthesis , Neprilysin/biosynthesis , Sweat Gland Neoplasms/metabolism , Adenoma, Sweat Gland/classification , Adenoma, Sweat Gland/metabolism , Adenoma, Sweat Gland/pathology , Humans , Sweat Gland Neoplasms/classification , Sweat Gland Neoplasms/pathology , Sweat Glands/metabolism , Sweat Glands/pathologySubject(s)
Pemphigoid Gestationis/immunology , Adult , Anti-Inflammatory Agents/administration & dosage , Diagnosis, Differential , Drug Therapy, Combination , Female , Fetus/immunology , Humans , Immune Tolerance , Pemphigoid Gestationis/diagnosis , Pemphigoid Gestationis/drug therapy , Pemphigoid Gestationis/pathology , Prednisone/administration & dosage , Pregnancy , Pregnancy OutcomeABSTRACT
BACKGROUND: Replicating smallpox vaccines can cause severe complications in individuals with atopic dermatitis (AD). Prior studies evaluating Modified Vaccinia Ankara virus (MVA), a non-replicating vaccine in humans, showed a favorable safety and immunogenicity profile in healthy volunteers. OBJECTIVE: This Phase II study compared the safety and immunogenicity of MVA enrolling groups of 350 subjects with AD (SCORAD ≤ 30) and 282 healthy subjects. METHODS: Subjects were vaccinated twice with MVA, each dose given subcutaneously 4 weeks apart. Adverse events, cardiac parameters, and the development of vaccinia virus humoral immune responses were monitored. RESULTS: The overall safety of the vaccine was similar in both groups. Adverse events affecting skin were experienced significantly more often in subjects with AD, but the majority of these events were mild to moderate in intensity. Seroconversion rates and geometric mean titers for total and neutralizing vaccinia-specific antibodies in the AD group were non-inferior compared to the healthy subjects. LIMITATIONS: The size of the study population limited the detection of serious adverse events occurring at a frequency less than 1%. CONCLUSION: MVA has a favorable safety profile and the ability to elicit vaccinia-specific immune responses in subjects with AD. TRIAL REGISTRATION: ClinicalTrials.gov NCT00316602.
Subject(s)
Dermatitis, Atopic/immunology , Dermatitis, Atopic/prevention & control , Vaccination , Vaccinia virus/immunology , Viral Vaccines/therapeutic use , Adolescent , Adult , Antibody Formation/immunology , Humans , Smallpox Vaccine/adverse effects , Smallpox Vaccine/standards , Smallpox Vaccine/therapeutic use , Viral Vaccines/adverse effects , Viral Vaccines/standards , Young AdultABSTRACT
As the population ages, the prevalence of bullous skin diseases will escalate. Efficient management depends on timely recognition by the physician and reduces the morbidity associated with the disease course. This article outlines the common bullous dermatoses affecting older adults and provides tips for a streamlined approach to workup and treatment.
Subject(s)
Dermatologic Agents/therapeutic use , Immunosuppressive Agents/therapeutic use , Skin Diseases, Vesiculobullous/diagnosis , Skin Diseases, Vesiculobullous/drug therapy , Skin/pathology , Aged , Aged, 80 and over , Biopsy , Diagnosis, Differential , Female , Humans , Immunoglobulin A/blood , Immunoglobulin G/blood , Male , Skin Diseases, Vesiculobullous/etiology , Skin Diseases, Vesiculobullous/pathologyABSTRACT
This article provides an overview of the diagnosis, epidemiology, and management of psoriasis, with a focus on the special characteristics of managing elderly patients. Complications particular to psoriasis patients and the side effects of treatment options are described.